Since ANXA1 inhibits phospholipase A2 activity as part of its anti-inflammatory action [33], [34] and PLA2 activity is increased in IBD colonic mucosa [35], we studied the potential effect of MC-12 on PLA2. Here, PLA2G4A is linked to inflammatory bowel disease.